Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation

Silodosin, a selective α1A-adrenergic blocker prescribed for the symptomatic treatment of benign prostatic hyperplasia, was previously shown to decrease the expression of ELK1, a c-fos proto-oncogene regulator and a well-described downstream target of the PKC/Raf-1/ERK pathway, in human prostate smo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Cancer Res
Autors principals: Kawahara, Takashi, Ide, Hiroki, Kashiwagi, Eiji, Patterson, John D, Inoue, Satoshi, Shareef, Hasanain Khaleel, Aljarah, Ali Kadhim, Zheng, Yichun, Baras, Alexander S, Miyamoto, Hiroshi
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4656723/
https://ncbi.nlm.nih.gov/pubmed/26693052
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars